

US011865280B2

(12) **United States Patent**  
**McNeil**

(10) **Patent No.:** **US 11,865,280 B2**  
(45) **Date of Patent:** **\*Jan. 9, 2024**

- (54) **LIMITED-ACCESS, REDUCED-PRESSURE SYSTEMS AND METHODS**
- (71) Applicant: **KCI Licensing, Inc.**, San Antonio, TX (US)
- (72) Inventor: **Bruce McNeil**, San Antonio, TX (US)
- (73) Assignee: **3M Innovative Properties Company**, Saint Paul, MN (US)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 481 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: **17/125,307**
- (22) Filed: **Dec. 17, 2020**

- (65) **Prior Publication Data**  
US 2021/0100939 A1 Apr. 8, 2021

**Related U.S. Application Data**

- (60) Continuation of application No. 15/651,585, filed on Jul. 17, 2017, now Pat. No. 10,898,624, which is a (Continued)
- (51) **Int. Cl.**  
*A61F 13/00* (2006.01)  
*A61M 1/00* (2006.01)  
(Continued)
- (52) **U.S. Cl.**  
CPC ..... *A61M 27/00* (2013.01); *A61F 13/00068* (2013.01); *A61F 13/0216* (2013.01);  
(Continued)
- (58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS

1,355,846 A 10/1920 Rannells  
2,547,758 A 4/1951 Keeling  
(Continued)

FOREIGN PATENT DOCUMENTS

AU 550575 B2 3/1986  
AU 745271 B2 3/2002  
(Continued)

OTHER PUBLICATIONS

Louis C. Argenta, MD and Michael J. Morykwas, PhD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; *Annals of Plastic Surgery*; vol. 38, No. 6, Jun. 1997; pp. 563-576.


(Continued)

*Primary Examiner* — Kim M Lewis

(57) **ABSTRACT**

A reduced-pressure treatment system for applying reduced pressure to a tissue site at a limited-access location on a patient includes a reduced-pressure source, a treatment manifold for placing proximate the tissue site and operable to distribute reduced pressure to the tissue site, and a sealing member for placing over the tissue site and operable to form a pneumatic seal over the tissue site. The reduced-pressure treatment system also includes a reduced-pressure bridge and a moisture-removing device on at least portion of the reduced-pressure bridge. The reduced-pressure bridge includes a delivery manifold operable to transfer the reduced pressure to the treatment manifold, an encapsulating envelope at least partially enclosing the delivery manifold and having a patient-facing side, and a reduced-pressure-interface site formed proximate one end of the reduced-pressure bridge.

**20 Claims, 8 Drawing Sheets**



**Related U.S. Application Data**

continuation of application No. 14/045,946, filed on Oct. 4, 2013, now Pat. No. 9,744,277, which is a continuation of application No. 13/348,306, filed on Jan. 11, 2012, now Pat. No. 8,575,416, which is a division of application No. 12/403,296, filed on Mar. 12, 2009, now Pat. No. 8,158,844.

(60) Provisional application No. 61/103,566, filed on Oct. 8, 2008.

(51) **Int. Cl.**

*A61M 27/00* (2006.01)

*A61F 13/02* (2006.01)

(52) **U.S. Cl.**

CPC ..... *A61M 1/913* (2021.05); *A61M 1/915* (2021.05); *A61M 1/92* (2021.05)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,632,443 A 3/1953 Leshner  
 2,682,873 A 7/1954 Evans et al.  
 2,910,763 A 11/1959 Lauterbach  
 2,969,057 A 1/1961 Simmons  
 3,066,672 A 12/1962 Crosby, Jr. et al.  
 3,367,332 A 2/1968 Groves  
 3,520,300 A 7/1970 Flower, Jr.  
 3,568,675 A 3/1971 Harvey  
 3,648,692 A 3/1972 Wheeler  
 3,682,180 A 8/1972 McFarlane  
 3,826,254 A 7/1974 Mellor  
 4,080,970 A 3/1978 Miller  
 4,096,853 A 6/1978 Weigand  
 4,139,004 A 2/1979 Gonzalez, Jr.  
 4,165,748 A 8/1979 Johnson  
 4,184,510 A 1/1980 Murry et al.  
 4,233,969 A 11/1980 Lock et al.  
 4,245,630 A 1/1981 Lloyd et al.  
 4,256,109 A 3/1981 Nichols  
 4,261,363 A 4/1981 Russo  
 4,275,721 A 6/1981 Olson  
 4,284,079 A 8/1981 Adair  
 4,297,995 A 11/1981 Golub  
 4,333,468 A 6/1982 Geist  
 4,373,519 A 2/1983 Errede et al.  
 4,382,441 A 5/1983 Svedman  
 4,392,853 A 7/1983 Muto  
 4,392,858 A 7/1983 George et al.  
 4,419,097 A 12/1983 Rowland  
 4,465,485 A 8/1984 Kashmer et al.  
 4,475,909 A 10/1984 Eisenberg  
 4,480,638 A 11/1984 Schmid  
 4,525,166 A 6/1985 Leclerc  
 4,525,374 A 6/1985 Vaillancourt  
 4,540,412 A 9/1985 Van Overloop  
 4,543,100 A 9/1985 Brodsky  
 4,548,202 A 10/1985 Duncan  
 4,551,139 A 11/1985 Plaas et al.  
 4,569,348 A 2/1986 Hasslinger  
 4,605,399 A 8/1986 Weston et al.  
 4,608,041 A 8/1986 Nielsen  
 4,640,688 A 2/1987 Hauser  
 4,655,754 A 4/1987 Richmond et al.  
 4,664,662 A 5/1987 Webster  
 4,710,165 A 12/1987 McNeil et al.  
 4,733,659 A 3/1988 Edenbaum et al.  
 4,743,232 A 5/1988 Kruger  
 4,758,220 A 7/1988 Sundblom et al.  
 4,787,888 A 11/1988 Fox  
 4,826,494 A 5/1989 Richmond et al.  
 4,838,883 A 6/1989 Matsuura  
 4,840,187 A 6/1989 Brazier  
 4,863,449 A 9/1989 Therriault et al.

4,872,450 A 10/1989 Austad  
 4,878,901 A 11/1989 Sachse  
 4,897,081 A 1/1990 Poirier et al.  
 4,906,233 A 3/1990 Moriuchi et al.  
 4,906,240 A 3/1990 Reed et al.  
 4,919,654 A 4/1990 Kalt  
 4,941,882 A 7/1990 Ward et al.  
 4,953,565 A 9/1990 Tachibana et al.  
 4,969,880 A 11/1990 Zamierowski  
 4,985,019 A 1/1991 Michelson  
 5,037,397 A 8/1991 Kalt et al.  
 5,086,170 A 2/1992 Luheshi et al.  
 5,092,858 A 3/1992 Benson et al.  
 5,100,396 A 3/1992 Zamierowski  
 5,134,994 A 8/1992 Say  
 5,149,331 A 9/1992 Ferdman et al.  
 5,167,613 A 12/1992 Karami et al.  
 5,176,663 A 1/1993 Svedman et al.  
 5,215,522 A 6/1993 Page et al.  
 5,232,453 A 8/1993 Plass et al.  
 5,261,893 A 11/1993 Zamierowski  
 5,278,100 A 1/1994 Doan et al.  
 5,279,550 A 1/1994 Habib et al.  
 5,298,015 A 3/1994 Komatsuzaki et al.  
 5,342,376 A 8/1994 Ruff  
 5,344,415 A 9/1994 DeBusk et al.  
 5,358,494 A 10/1994 Svedman  
 5,437,622 A 8/1995 Carion  
 5,437,651 A 8/1995 Todd et al.  
 5,527,293 A 6/1996 Zamierowski  
 5,549,584 A 8/1996 Gross  
 5,556,375 A 9/1996 Ewall  
 5,607,388 A 3/1997 Ewall  
 5,636,643 A 6/1997 Argenta et al.  
 5,645,081 A 7/1997 Argenta et al.  
 6,071,267 A 6/2000 Zamierowski  
 6,135,116 A 10/2000 Vogel et al.  
 6,241,747 B1 6/2001 Ruff  
 6,287,316 B1 9/2001 Agarwal et al.  
 6,345,623 B1 2/2002 Heaton et al.  
 6,488,643 B1 12/2002 Tumey et al.  
 6,493,568 B1 12/2002 Bell et al.  
 6,553,998 B2 4/2003 Heaton et al.  
 6,814,079 B2 11/2004 Heaton et al.  
 7,846,141 B2 12/2010 Weston  
 8,062,273 B2 11/2011 Weston  
 8,216,198 B2 7/2012 Heagle et al.  
 8,251,979 B2 8/2012 Malhi  
 8,257,327 B2 9/2012 Blott et al.  
 8,398,614 B2 3/2013 Blott et al.  
 8,449,509 B2 5/2013 Weston  
 8,529,548 B2 9/2013 Blott et al.  
 8,535,296 B2 9/2013 Blott et al.  
 8,551,060 B2 10/2013 Schuessler et al.  
 8,568,386 B2 10/2013 Malhi  
 8,679,081 B2 3/2014 Heagle et al.  
 8,834,451 B2 9/2014 Blott et al.  
 8,926,592 B2 1/2015 Blott et al.  
 9,017,302 B2 4/2015 Vitaris et al.  
 9,198,801 B2 12/2015 Weston  
 9,211,365 B2 12/2015 Weston  
 9,289,542 B2 3/2016 Blott et al.  
 10,898,624 B2\* 1/2021 McNeil ..... A61M 27/00  
 2002/0077661 A1 6/2002 Saadat  
 2002/0115951 A1 8/2002 Norstrem et al.  
 2002/0120185 A1 8/2002 Johnson  
 2002/0143286 A1 10/2002 Tumey  
 2004/0030304 A1\* 2/2004 Hunt ..... A61F 13/00068  
 2014/0163491 A1 6/2014 Schuessler et al. 604/317  
 2015/0080788 A1 3/2015 Blott et al.

FOREIGN PATENT DOCUMENTS

AU 755496 B2 12/2002  
 CA 2005436 A1 6/1990  
 DE 26 40 413 A1 3/1978  
 DE 43 06 478 A1 9/1994  
 DE 29 504 378 U1 9/1995

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

EP	0100148	A1	2/1984
EP	0117632	A2	9/1984
EP	0161865	A2	11/1985
EP	0358302	A2	3/1990
EP	1018967	A1	7/2000
GB	692578	A	6/1953
GB	2195255	A	4/1988
GB	2 197 789	A	6/1988
GB	2 220 357	A	1/1990
GB	2 235 877	A	3/1991
GB	2 329 127	A	3/1999
GB	2 333 965	A	8/1999
JP	4129536	B2	8/2008
SG	71559		4/2002
WO	80/02182	A1	10/1980
WO	87/04626	A1	8/1987
WO	90/010424	A1	9/1990
WO	93/009727	A1	5/1993
WO	94/20041	A1	9/1994
WO	96/05873	A1	2/1996
WO	97/18007	A1	5/1997
WO	99/13793	A1	3/1999

## OTHER PUBLICATIONS

Susan Mendez-Eatmen, RN; "When wounds Won't Heal" RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.

James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; *Annals of Plastic Surgery*, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philadelphia, PA, USA.

John Masters; "Reliable, Inexpensive and Simple Suction Dressings"; Letter to the Editor, *British Journal of Plastic Surgery*, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.

S.E. Greer, et al. "The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin" *British Journal of Plastic Surgery* (2000), 53, pp. 484-487.

George V. Letsou, MD., et al; "Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch"; *Journal of Cardiovascular Surgery*, 31, 1990, pp. 634-639.

Orringer, Jay, et al; "Management of Wounds in Patients with Complex Enterocutaneous Fistulas"; *Surgery, Gynecology & Obstetrics*, Jul. 1987, vol. 165, pp. 79-80.

International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995.

PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999.

PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999.

PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997.

PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997.

Dattilo, Philip P., Jr., et al; "Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture"; *Journal of Textile and Apparel, Technology and Management*, vol. 2, Issue 2, Spring 2002, pp. 1-5.

Kostyuchenok, B.M., et al; "Vacuum Treatment in the Surgical Management of Purulent Wounds"; *Vestnik Khirurgi*, Sep. 1986, pp. 18-21 and 6 page English translation thereof.

Davydov, Yu. A., et al; "Vacuum Therapy in the Treatment of Purulent Lactation Mastitis"; *Vestnik Khirurgi*, May 14, 1986, pp. 66-70, and 9 page English translation thereof.

Yusupov, Yu.N., et al; "Active Wound Drainage"; *Vestnik Khirurgi*, vol. 138, Issue 4, 1987, and 7 page English translation thereof.

Davydov, Yu.A., et al; "Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds"; *Vestnik Khirurgi*, Oct. 1988, pp. 48-52, and 8 page English translation thereof.

Davydov, Yu.A., et al; "Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy"; *Vestnik Khirurgi*, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.

Chariker, Mark E., M.D., et al; "Effective Management of incisional and cutaneous fistulae with closed suction wound drainage"; *Contemporary Surgery*, vol. 34, Jun. 1989, pp. 59-63.

Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.

Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.

Svedman, P.: "Irrigation Treatment of Leg Ulcers", *The Lancet*, Sep. 3, 1983, pp. 532-534.

Chinn, Steven D. et al.: "Closed Wound Suction Drainage", *The Journal of Foot Surgery*, vol. 24, No. 1, 1985, pp. 76-81.

Arnljots, Björn et al.: "Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers", *Scand J. Plast Reconstr. Surg.*, No. 19, 1985, pp. 211-213.

Svedman, P.: "A Dressing Allowing Continuous Treatment of a Biosurface", *IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation*, vol. 7, 1979, p. 221.

Svedman, P. et al: "A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation", *Annals of Plastic Surgery*, vol. 17, No. 2, Aug. 1986, pp. 125-133.

N.A. Bagautdinov, "Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues," *Current Problems in Modern Clinical Surgery: Interdepartmental Collection*, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation).

K.F. Jeter, T.E. Tintle, and M. Chariker, "Managing Draining Wounds and Fistulae: New and Established Methods," *Chronic Wound Care*, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.

G. Živadnovi?, V. ?uki?, Ž. Maksimovi?, ?. Radak, and P. Peška, "Vacuum Therapy in the Treatment of Peripheral Blood Vessels," *Timok Medical Journal* 11 (1986), pp. 161-164 (copy and certified translation).

F.E. Johnson, "An Improved Technique for Skin Graft Placement Using a Suction Drain," *Surgery, Gynecology, and Obstetrics* 159 (1984), pp. 584-585.

A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation).

M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, "The 'Sandwich Technique' in the Management of the Open Abdomen," *British Journal of Surgery* 73 (1986), pp. 369-370.

D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, *Archives of Surgery* 105 (1972) pp. 511-513.

M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, "Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation," *Annals of Plastic Surgery* 38 (1997), pp. 553-562 (Morykwas I).

C.E. Tennants, "The Use of Hyperemia in the Postoperative Treatment of Lesions of the Extremities and Thorax," *Journal of the American Medical Association* 64 (1915), pp. 1548-1549.

Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.

V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) ("Solovev Guidelines").

V.A. Kuznetsov & N.A. Bagautdinov, "Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds," in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 ("Bagautdinov II").

(56)

**References Cited**

OTHER PUBLICATIONS

V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) ("Solovev Abstract").  
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007.

\* cited by examiner










FIG. 1





















1

**LIMITED-ACCESS, REDUCED-PRESSURE  
SYSTEMS AND METHODS**

## RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/651,585 filed Jul. 17, 2017, which is a continuation of U.S. patent application Ser. No. 14/045,946, filed Oct. 4, 2013, now U.S. Pat. No. 9,744,277, which is a continuation of U.S. patent application Ser. No. 13/348,306, filed Jan. 11, 2012, now U.S. Pat. No. 8,575,416, which is a divisional application of U.S. patent application Ser. No. 12/403,296, filed Mar. 12, 2009, now U.S. Pat. No. 8,158,844, entitled "Limited-Access, Reduced Pressure Systems and Methods", which claims the benefit under 35 USC § 119(e) of the filing of U.S. Provisional Patent Application No. 61/103,566, filed Oct. 8, 2008, entitled "System and Method for Applying Reduced Pressure to a Patient's Limb, Such As a Foot." The entire contents of each of the applications referenced above are incorporated herein by reference for all purposes.

## BACKGROUND

The present invention relates generally to medical treatment systems and, more particularly, but not by way of limitation, to limited-access, reduced-pressure systems and methods.

Clinical studies and practices have shown that providing reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as "negative pressure wound therapy," "reduced pressure therapy," or "vacuum therapy") provides a number of benefits, which may include faster healing and increased formulation of granulation tissue. Unless otherwise indicated, as used herein, "or" does not require mutual exclusivity.

Providing reduced pressure to limited-access locations has been difficult. One example of a difficult limited-access location is the bottom sole (plantar) of a patient's foot or other anatomical locations that are difficult to service. A related illustrative example of a limited-access location is inside an offloading device, such as a walking boot or removable walker. Another example of a limited-access location is a tissue site on a bed-ridden patient's back. Other illustrative examples include a tissue site under a compression garment and sacral wounds on the foot.

## SUMMARY

Problems with existing reduced-pressure treatment devices and systems are addressed by the systems, apparatus, and methods of the illustrative embodiments described herein. According to an illustrative embodiment, a reduced-pressure treatment system for applying reduced pressure to a tissue site at a limited-access location on a patient includes a reduced-pressure source, a treatment manifold for placing proximate the tissue site and operable to distribute reduced pressure to the tissue site, and a sealing member for placing over the tissue site and operable to form a pneumatic seal over the tissue site. The reduced-pressure treatment system also includes a reduced-pressure bridge that includes a delivery manifold operable to transfer the reduced pressure to the treatment manifold, an encapsulating envelope at least

2

partially enclosing the delivery manifold and having a patient-facing side, a reduced-pressure-interface site formed proximate one end of the reduced-pressure bridge. The reduced-pressure treatment system also includes a moisture-removing device.

According to another illustrative embodiment, a reduced-pressure bridge for delivering reduced pressure to a reduced-pressure dressing from a remote site includes a delivery manifold operable to transfer a reduced pressure and an encapsulating envelope at least partially enclosing the delivery manifold and having a patient-facing side. A reduced-pressure-interface site is formed proximate a second end of the reduced-pressure bridge. The encapsulating envelope has a second aperture formed on the patient-facing side of the encapsulating envelope. The reduced-pressure bridge also includes a moisture-removing device on at least a portion of the encapsulating envelope.

According to another illustrative embodiment, a method for delivering reduced pressure to a tissue site at a limited-access location includes the steps of: disposing a first manifold proximate the wound and disposing a sealing member over the first manifold. The sealing member has a first aperture. The method for delivering reduced pressure to a tissue site further includes providing a reduced-pressure bridge having a first end and a second end. The reduced-pressure bridge has a second aperture proximate the first end, a moisture-removing device, and a second manifold. The method for delivering reduced pressure to a tissue site further includes coupling a reduced-pressure interface to the second end of the reduced-pressure bridge; disposing the first end of the reduced-pressure bridge over at least a portion of the sealing member with the second aperture substantially aligned with the first aperture. The first manifold may be at least partially encapsulated with an encapsulating envelope that has a patient-facing side. The method for delivering reduced pressure to a tissue site may further include fluidly coupling a reduced-pressure source to the reduced-pressure interface.

According to another illustrative embodiment, a reduced-pressure treatment kit includes a reduced-pressure bridge, the reduced-pressure bridge, a reduced-pressure interface, a reduced-pressure delivery conduit, a manifold unit, and a perforated sealing sheet. The manifold unit has a plurality of preformed treatment manifolds. The perforated sealing sheet is operable to be torn into a plurality of securing strips and a sealing member.

Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic, perspective view with a portion shown as a block diagram of an illustrative reduced-pressure treatment system utilizing a reduced-pressure bridge;

FIG. 2A is schematic, plan view of an illustrative reduced-pressure bridge;

FIG. 2B is a schematic, perspective, exploded view of the illustrative reduced-pressure bridge of FIG. 2A;

FIG. 2C is a schematic, cross-sectional view taken along line 2C-2C of the illustrative reduced-pressure bridge of FIG. 2A;

FIG. 2D is a schematic, cross-sectional view of an alternative illustrative reduced-pressure bridge;

FIG. 3 is schematic, perspective view showing an illustrative reduced-pressure bridge being coupled with a reduced-pressure interface;

FIG. 4 is a schematic, plan view of the reduced-pressure bridge of FIG. 3 with the reduced-pressure interface installed;

FIG. 5 is a schematic diagram of an illustrative reduced-pressure treatment system utilizing a reduced-pressure bridge shown on a traverse section through an abdomen of a patient on a bed;

FIG. 6 is a schematic diagram of an illustrative embodiment of a reduced-pressure treatment kit for use with limited-access tissue sites;

FIG. 7A is a schematic, perspective view of an illustrative manifold unit; and

FIG. 7B is a schematic plan view of the manifold unit of FIG. 7A.

#### DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.

Referring to FIG. 1, an illustrative embodiment of a reduced-pressure treatment system 100 is presented. The reduced-pressure treatment system 100 has an illustrative embodiment of a reduced-pressure bridge 102. The reduced-pressure bridge 102 facilitates reduced-pressure treatment of a tissue site 104 and in particular a limited-access tissue site, which in this illustration is on the bottom sole (plantar) of a patient's foot 106 and also within an offloading device, e.g., offloading boot 108 (shown in hidden lines). The reduced-pressure treatment system 100 may be used with a tissue site at a non-limited-access site or a limited-access site. Other illustrative examples of limited-access tissue sites include on a patient's back, under a compression garment, in a total contact casting (TCC), in a removable walker, in a healing sandal, in a half shoe, in an ankle foot orthoses, etc. The reduced-pressure treatment system 100 may be used with the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue.

The reduced-pressure bridge 102 provides a low profile source of reduced pressure to be supplied to the limited-access tissue site 104 and thereby may increase patient comfort and enhance reliability of the reduced-pressure supply to the limited-access tissue site 104. Because of the low profile of the reduced-pressure bridge 102, the reduced-pressure bridge 102 may readily be used with an offloading device. As such, the reduced-pressure bridge 102 may allow the patient the benefit of both reduced-pressure treatment as well as the offloading of physical pressure. As described further below, the reduced-pressure bridge 102 may include a moisture-removing device, e.g., moisture-removing device 216 in FIG. 2B, that helps to avoid maceration of a patient's skin by removing moisture from the patient's skin.

The reduced-pressure bridge 102 has a first end 110 that is placed proximate the limited-access tissue site 104 and a second end 112. The second end 112 has a reduced-pressure-interface site 114 that is for receiving a reduced-pressure interface 116, which may be a port, such as a TRAC Pad® interface or a SensaT.R.A.C.™ pad interface from Kinetic Concepts, Inc. of San Antonio, Texas. The second end 112 is typically placed at a location on or near the patient that provides convenient access by the healthcare provider, such as a convenient location for applying reduced-pressure to the reduced-pressure-interface site 114. When an offloading device, e.g., offloading boot 108, is utilized, the reduced-pressure bridge 102 would extend from the tissue site to a place outside of the offloading device. The actual length (L) of the reduced-pressure bridge 102 may be varied to support use with a particular offloading device or application.

A reduced-pressure delivery conduit 118 may fluidly couple the reduced-pressure interface 116 to a reduced-pressure source 120. The reduced-pressure source 120 may be any device or means for supplying a reduced pressure, such as a vacuum pump or wall suction. While the amount and nature of reduced pressure applied to a site will vary according to the application, the reduced pressure will typically be between -5 mm Hg and -500 mm Hg or more typically between -25 mm Hg to -200 mm Hg. For vertical applications of the reduced-pressure bridge 102, such as is shown in FIG. 1 on an ambulatory patient's leg, a specified minimum reduced pressure may be necessary to ensure proper fluid flow. For example in one embodiment, a reduced pressure of at least -125 mm Hg has been suggested as a minimum, but other pressures may be suitable for different situations. As used herein, "reduced pressure" generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Although the terms "vacuum" and "negative pressure" may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure. In one illustrative embodiment, a V.A.C.® Therapy Unit by Kinetic Concepts, Inc. of San Antonio may be used as the reduced-pressure source 120.

Depending on the application, a plurality of devices may be fluidly coupled to the reduced-pressure delivery conduit 118. For example, a fluid canister 122 or a representative device 124 may be included. The representative device 124 may be another fluid reservoir or canister to hold exudates and other fluids removed. Other examples of device 124 that may be included on the reduced-pressure delivery conduit 118 include the following non-limiting examples: a pressure-feedback device, a volume detection system, a blood detection system, an infection detection system, a flow monitoring system, a temperature monitoring system, a filter, etc. Some of these devices may be formed integral to the reduced-pressure source 120. For example, a reduced-pressure port 126 on the reduced-pressure source 120 may include a filter member that includes one or more filters, e.g., an odor filter.

Referring now to FIGS. 2A-2C, an illustrative, reduced-pressure bridge 200 will be presented. The illustrative, reduced-pressure bridge 200 has a first end 202 and a second

5

end **204**. The first end **202** of the illustrative, reduced-pressure bridge **200** is configured to provide reduced pressure to a first manifold, or treatment manifold (e.g., treatment manifold **310** in FIG. **5**) and the second end **204** has a reduced-pressure-interface site **206**.

Referring primarily to FIG. **2B**, the layers that make up the illustrative, reduced-pressure bridge **200** are presented. A first encapsulating member **210** is on a first side **208** of the illustrative, reduced-pressure bridge **200**. The first encapsulating member **210** may have an aperture **211** formed proximate the second end **204**. A second manifold, or delivery manifold **212**, is disposed proximate the first encapsulating member **210**. A second encapsulating member **214** is disposed proximate a second side of the delivery manifold **212**. The second encapsulating member **214** may be formed with an aperture **213** proximate the first end **202**. A moisture-removing device **216** is disposed proximate the second encapsulating member **214**, which in this illustrative embodiment is a wicking layer **218**. A releasable backing member or release liner **220** may be included on the first end **202** to releasably cover an adhesive as is explained further below. The releasable backing member **220** may be formed with an aperture **222** that aligns with the aperture **213** in the second encapsulating member **214**.

The delivery manifold **212** may be any material capable of transferring reduced pressure. In one embodiment, the delivery manifold **212** is a foam material, such as a GranuFoam® material from Kinetic Concepts, Inc. of San Antonio, Texas. The delivery manifold **212** may be formed from the same material as a treatment manifold (e.g., treatment manifold **310** in FIG. **5**). The delivery manifold **212** may have any thickness, such as a thickness in the range of 3-20 millimeters, 5-10 millimeters, 6-7 millimeters, etc. The thickness of the delivery manifold **212** may be varied to minimize or eliminate pressure points on the tissue site. The thickness of the delivery manifold **212** may also be selected to support fluid removal from the tissue site and transfer into a canister (e.g., fluid canister **122** in FIG. **1**).

The first encapsulating member **210** and the second encapsulating member **214** may be composed of any material that facilitates maintaining reduced pressure within a first encapsulating envelope **229** formed from the first encapsulating member **210** and the second encapsulating member **214**. In one embodiment, the first encapsulating member **210** and the second encapsulating member **214** include a polyurethane film, but any suitable drape material may be readily used, such as any natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, silicones, 3M Tegaderm® drape material, or acrylic drape material, such as one available from Avery. These are non-limiting examples.

Referring now primarily to FIGS. **2A** and **2C**, a periphery portion **224** of the first encapsulating member **210** and a periphery portion **226** of the second encapsulating member **214** may be coupled, such as by RF weld **228**, to form the first encapsulating envelope **229**. As used herein, the term “coupled” includes coupling via a separate object and includes direct coupling. The term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term “coupled” may include chemical, mechanical, or thermal coupling. Fluid coupling means that fluid is in communication between the designated parts or locations. The first encap-

6

ulating member **210** and the second encapsulating member **214** may be coupled using any technique, including without limitation welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc. The first encapsulating envelope **229** may completely enclose the delivery manifold **212**. The moisture-removing device **216** may be coupled to at least a portion of the first encapsulating envelope **229** using any technique. The wicking layer may be coupled to a patient-facing side **230** of the second encapsulating member **214** of the first encapsulating envelope **229**.

The moisture-removing device **216** pulls moisture, e.g., perspiration, away from a patient's skin and thereby helps to avoid maceration of the patient's skin and enhances comfort. The extent of the wicking layer **218** can be varied both laterally (width) and longitudinally (lengthwise). For example, the wicking layer **218** may cover 100 percent or more than 90 percent, 80 percent, 70 percent, 60 percent, or 50 percent of the patient-facing second encapsulating member **214**. The wicking layer **218** pulls moisture to a place where the moisture can evaporate more readily. In the illustrative embodiment of FIGS. **2A-2C**, the moisture-removing device **216** is the wicking layer **218**. For example, the wicking layer **218** may be a cloth-material drape, a non-woven fabric, a knitted polyester woven textile material, such as the one sold under the name InterDry® AG material from Coloplast A/S of Denmark, GORTEX® material, DuPont Softesse® material, etc.

Referring now to FIG. **2D**, an alternative embodiment of the moisture-removing device **216** is presented. In this embodiment, a third encapsulating member **232** is provided with a plurality of apertures or fenestrations **234**. The third encapsulating member **232** covers all or at least a portion of a third manifold **236**, or comfort manifold. A periphery portion of the third encapsulating member **232** is also coupled by any technique, such as by RF weld **228**. In conjunction with the second encapsulation member **214**, the third encapsulation member **232** forms a second encapsulating envelope **238**. In operation, a reduced pressure is supplied within the second encapsulation member **214** and any fluid against a patient's skin is pulled through the plurality of apertures **234** into the third manifold **236** and delivered elsewhere, e.g., to a canister, for storage or disposal.

In still another alternative embodiment of the moisture-removal device **216**, a moisture vapor permeable material is pneumatically coupled to a negative pressure source to provide active removal adjacent the illustrative, reduced-pressure bridge **200**. In still another illustrative embodiment, apertures may be formed on the second encapsulating member **214** that allow the reduced pressure in the first encapsulating envelope **229** to pull fluids into the delivery manifold **212**. In still another illustrative embodiment of a moisture-removing device, apertures may be formed in the second encapsulating member **214** that allow the reduced pressure in the first encapsulating envelope **229** to pull fluids into the delivery manifold **212**, and reduced-pressure valves may be associated with the apertures that close when reduced pressure is absent.

Referring again primarily to FIGS. **2A-2C**, the illustrative, reduced-pressure bridge **200** has a length (L), a width (W), and a thickness (T). The illustrative, reduced-pressure bridge **200** preferably has a low of profile, e.g., small dimension T, as possible. For non-limiting examples, T may be 30 mm, 20 mm, 15 mm, 10 mm, 5 mm, or less. In other embodiments, T may take any size. Moreover, the comfort or function of the illustrative, reduced-pressure bridge **200** may be enhanced by using a length (L) to width (W) ratio

that involves having the length dimension greater than the width. For example, in one embodiment, the relationship is  $L > 2 W$ . In another illustrative embodiment, the relationship is  $L > 6 W$ . In another illustrative embodiment, the relationship is  $L > 12 W$ . In another illustrative embodiment, the relationship is  $L > 15 W$ . In one illustrative embodiment,  $L$  is approximately 668 mm and  $W$  is approximately 56 mm.

Referring now to FIG. 3, the illustrative reduced-pressure bridge 200 is shown with a reduced-pressure interface 240 about to be coupled to the reduced-pressure-interface site 206 of the illustrative, reduced-pressure bridge 200. The aperture 211 in the first encapsulating member 210 substantially aligns with a central portion of the reduced-pressure interface 240 to provide a fluid coupling. A reduced-pressure delivery conduit 242 is coupled at one end to the reduced-pressure interface 240 and at the other end has a fitting 244 that facilitates coupling to a reduced-pressure source (not shown). A restricting clip or clamp 246 and a visual indicia flag 248 may also be included on a portion of the reduced-pressure delivery conduit 242. FIG. 4 shows a plan view with the reduced-pressure interface 240 coupled to the reduced-pressure-interface site 206.

Referring now to FIG. 5, a reduced-pressure treatment system 300 is presented. The reduced-pressure treatment system 300 is shown deployed to treat a tissue site 302 on a patient's back 304. If the patient is bed-ridden, the patient's back 304 may be pressed against a portion of a bed 306. In such a situation, the use of a reduced-pressure bridge 308, or transfer member, as part of the reduced-pressure treatment system 300 may be particularly beneficial to the patient. The reduced-pressure bridge 308 is analogous to the illustrative, reduced-pressure bridge 200 presented above.

A treatment manifold 310 is disposed proximate the tissue site 302. A sealing member 312 having an attachment device 314 on a patient-facing side is disposed over the treatment manifold 310. The term "manifold" as used herein generally refers to a substance or structure that helps to distribute reduced-pressure and to transport fluids. The treatment manifold 310 typically includes a plurality of flow channels or pathways that are interconnected to improve distribution of fluids provided to and removed from the tissue site 302 around the treatment manifold 310. The treatment manifold 310 may be a biocompatible material that is capable of being placed in contact with the tissue site 302 and distributing reduced pressure to the tissue site 302. Examples of treatment manifolds 310 may include, for example, without limitation, devices that have structural elements arranged to form flow channels, such as, for example, cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. The treatment manifold 310 may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. In one embodiment, the treatment manifold 310 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam, such as a GranuFoam® material manufactured by Kinetic Concepts, Incorporated of San Antonio, Texas. In some situations, the treatment manifold 310 may also be used to distribute fluids, such as medications, antibacterials, growth factors, and various solutions to the tissue site 302.

The attachment device 314 may be used to hold the sealing member 312 against the patient's epidermis or another layer, such as a gasket or additional sealing member.

The attachment device 314 may take numerous forms, e.g., a medically acceptable, pressure-sensitive adhesive, cement, hydrocolloid, etc.

The sealing member 312 and the attachment device 314 are formed with a first aperture 318. The sealing member 312 may be any material that provides a pneumatic seal. The sealing member may, for example, be an impermeable or semi-permeable, elastomeric material that has pore sizes less than about 20 microns. "Elastomeric" means having the properties of an elastomer. Elastomeric material, or elastomers, generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have elongation rates greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of sealing member materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as one available from Avery Dennison, or an incise drape.

The reduced-pressure bridge 308 has a first end 320 and a second end 322. A first encapsulating member 324 is coupled to a second encapsulating member 326 to form an encapsulating envelope 328. The first encapsulating envelope 328 encloses, at least in part, a delivery manifold 330. The second encapsulating member 326 has a second aperture 332 proximate the first end 320. The second aperture 332 is sized and configured to align with the first aperture 318. A reduced-pressure interface 334 is fluidly coupled at a reduced-pressure-interface site 336. The reduced-pressure interface 334 is fluidly coupled to a third aperture 338. A reduced-pressure delivery conduit 340 fluidly couples a reduced-pressure source (not shown) to the reduced-pressure interface 334. A moisture-removing device 342 is coupled to the patient-facing side of the encapsulating envelope 328 and in particular to the second encapsulating member 326.

Referring now to FIG. 6, a schematic diagram of an illustrative embodiment of a reduced-pressure treatment kit 400 for use with limited-access tissue sites is presented. The reduced-pressure treatment kit 400 facilitates organized and efficient application of reduced pressure to a tissue site and particularly to a limited-access tissue site. The reduced-pressure treatment kit 400 may include a sealed package or container that is opened by a healthcare provider. The reduced-pressure treatment kit 400 may include a reduced-pressure bridge 402, a reduced-pressure interface 404, a reduced-pressure delivery conduit 408, a ruler 416, a manifold unit 418, and a perforated sealing sheet 420, or any combination thereof. The ruler 416 may be used to help size the dimensions of the wound and may provide other information to help assess a wound.

The reduced-pressure bridge 402 may be analogous the reduced-pressure bridges 102, 200, and 308 previously presented. The reduced-pressure bridge 402 has a first end 403 and a second end 405. A reduced-pressure interface 404 may be coupled to a reduced-pressure-interface site 406 on the reduced-pressure bridge 402. The reduced-pressure delivery conduit 408 may be coupled to the reduced-pressure interface 404. The reduced-pressure delivery conduit 408 may include a visual indicia flag or label 410 and restricting clip or clamp 412. A fitting 414 may be coupled at one end of the reduced-pressure delivery conduit 408 to



facilitate coupling to a reduced-pressure source (not shown). That the reduced-pressure bridge **402** is already encapsulated as provided in the reduced-pressure treatment kit **400** allows for easy application and requires minimal work to deploy the reduced-pressure bridge **402**.

The perforated sealing sheet **420** has adhesive on a patient-facing side and has a releasable backing or release liner that covers the adhesive until it is ready for application. A plurality of perforations, e.g., mid-line perforation **422**, provides a location where the healthcare provider may readily tear the perforated sealing sheet **420** to form new members. Thus, for example, a portion of the mid-line perforation **422**, a first longitudinal perforation **424**, and a portion of an end perforation **426** may be torn to form a first sealing member **428**, which has an aperture **430**. The sealing member **428** may be used to secure a treatment manifold in place. Other longitudinal perforations **432** may be torn to form securing strips **434** that are used to hold the reduced-pressure bridge **402** in place as will be described further below.

The illustrative manifold unit **418**, which is also shown in FIGS. 7A and 7B, is made of a manifold material. For example, the manifold unit **418** may be formed from a reticulated foam, such as a Granufoam® material from Kinetic Concepts, Inc. of San Antonio, Texas. The manifold unit **418** has a number of pre-cut manifold components that may be used. For example, a first treatment manifold **436** is formed and has a connection stem **438** that be readily torn. Numerous additional treatment manifolds, e.g., second treatment manifold **440** and third treatment manifold **442**, may be included. A mid-portion of the manifold unit **418** may have a precut **444**, which is cut all the way through except for a small tag or portion **446** used to hold the manifold unit **418** together until torn. When the stems, e.g., stem **438**, are torn and the tag **446** is torn, two manifold blocks **448** and **450** are formed.

Referring now primarily to FIGS. 5 and 6, an illustrative deployment of a reduced-pressure treatment system, such as the reduced-pressure treatment system **300**, will be described. The wound or tissue site (e.g., tissue site **302** in FIG. 5) may first be prepared, such by removal of any other dressings and debriding the wound and the peri-wound area. The wound or tissue may be assessed with respect to size and condition.

The perforations, e.g., midline perforation **422**, on the perforated sealing sheet **420** are torn. Tearing the perforations produces the sealing member **428**, which has aperture **430**, a plurality of securing strips **434**, and an additional sealing member **429**.

A treatment manifold (e.g., treatment manifold **310** in FIG. 5) is placed proximate the tissue site, e.g., a wound. Depending on the size, the healthcare provider may tear off the first treatment manifold **436**, second treatment manifold, **440**, or third treatment manifold **442** from the manifold unit **418** in the reduced-pressure treatment kit **400**. If the size is notably different, a custom treatment manifold may be cut from one of the manifold blocks **448**, **450**. The properly sized treatment manifold is placed proximate the tissue site. If more than one treatment manifold is used, the number may be recorded on the visual indicia flag **410**. Then, the sealing member **428** is attached over the wound or tissue site **302** with the aperture **430** centered thereon. The sealing member **428** may first need to be trimmed to an appropriate size, which in one embodiment provides a 3-5 mm border around the tissue site. To attach the sealing member **428**, the release liner may be removed and the adhesive placed against a portion of intact epidermis; this is analogous to the

attachment device **314** being used to attach the sealing member **312** to the epidermis in FIG. 5. The reduced-pressure bridge, e.g., reduced-pressure bridge **402**, is then installed.

A release liner (e.g., release liner **220** in FIG. 2B) is removed exposing an adhesive on the first end **403** of the reduced-pressure bridge **402**, and an aperture (e.g., aperture **213** in FIG. 2B) on the reduced-pressure bridge **402** is substantially aligned with the aperture **430** on the sealing member **428** (e.g., sealing member **312** in FIG. 5) and then the first end **403** pressed against the sealing member **428**. The second end **405** of the reduced-pressure bridge **402** is placed at a convenient location and the securing strips **434** are used to secure the reduced-pressure bridge **402** in the desired location and at a point in between as desired. If the reduced-pressure bridge **402** is longer than desired, a fold shaped like a "Z" may be added into the reduced-pressure bridge **402** to shorten the effective length.

A reduced-pressure source (e.g., reduced-pressure source **120** in FIG. 1) may then be provided and the fitting **414** on the reduced-pressure delivery conduit **408** coupled to the reduced-pressure source or to another conduit supplying reduced pressure. The reduced-pressure source may then be activated.

Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims.

I claim:

1. A reduced-pressure bridge for delivering reduced pressure to a tissue site from a remote site, the reduced-pressure bridge comprising:
  - a first encapsulating envelope at least partially enclosing a first manifold;
  - a second encapsulating envelope at least partially enclosing a second manifold;
  - a first aperture proximate a first end of the reduced-pressure bridge and configured to be directly coupled to a sealing member that is configured to provide a fluid seal over the tissue site;
  - a second aperture proximate a second end of the reduced-pressure bridge and configured to be coupled to a reduced-pressure interface positioned at the remote site; and
  - a fenestration positioned between the first end and the second end.
2. The reduced-pressure bridge of claim 1, further comprising a wicking material on the reduced-pressure bridge.
3. The reduced-pressure bridge of claim 2, wherein the wicking material is adapted to contact a remote tissue portion and to absorb liquid from the remote tissue portion.
4. The reduced-pressure bridge of claim 2, wherein the wicking material comprises a cloth-material drape.
5. The reduced-pressure bridge of claim 2, wherein the wicking material comprises a non-woven fabric.
6. The reduced-pressure bridge of claim 2, wherein the wicking material covers at least 50 percent of a side of the reduced-pressure bridge.
7. The reduced-pressure bridge of claim 2, wherein the wicking material covers at least 70 percent of a side of the reduced-pressure bridge.
8. The reduced-pressure bridge of claim 2, wherein the wicking material covers at least 80 percent of a side of the reduced-pressure bridge.

**11**

9. The reduced-pressure bridge of claim 2, wherein the wicking material extends along a length of the reduced-pressure bridge.

10. The reduced-pressure bridge of claim 1, wherein the first encapsulating envelope and the second encapsulating envelope comprise a polyurethane material.

11. The reduced-pressure bridge of claim 1, wherein the reduced-pressure bridge has a length (L), and wherein  $L > 120$  mm.

12. The reduced-pressure bridge of claim 1, wherein the reduced-pressure bridge has a length (L), and wherein  $L > 200$  mm.

13. The reduced-pressure bridge of claim 1, wherein the reduced-pressure bridge has a length (L) and a width (W), and wherein  $L > (4 * W)$ .

14. The reduced-pressure bridge of claim 1, wherein the first manifold is a foam material.

15. The reduced-pressure bridge of claim 1, wherein the first encapsulating envelope is formed by a first encapsulating member and a second encapsulating member, and

**12**

wherein the second encapsulating envelope is formed by the second encapsulating member and a third encapsulating member.

16. The reduced-pressure bridge of claim 15, wherein the first encapsulating member has a first perimeter portion, wherein the second encapsulating member has a second perimeter portion, and wherein the first perimeter portion is coupled to the second perimeter portion.

17. The reduced-pressure bridge of claim 1, wherein the first aperture is configured to be in fluid communication with the tissue site through the sealing member.

18. The reduced-pressure bridge of claim 1, further comprising an adhesive on the first end configured to couple the reduced-pressure bridge to the sealing member.

19. The reduced-pressure bridge of claim 1, wherein the reduced-pressure bridge is configured to transfer reduced pressure from the remote location to the tissue site through the first aperture.

20. The reduced-pressure bridge of claim 1, wherein the reduced-pressure bridge is configured to distribute fluids to the tissue site.

\* \* \* \* \*